A Large Language Model-based Chatbot for Alcohol Reduction in Patients With Metabolic Alcohol-Related Liver Disease
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: LLM-based chatbot, Telephone counseling, Alcohol Brief Intervention.
- Who it may be relevant to
- Registry conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Alcohol-Related Liver Disease. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Hong Kong
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Large Language Model-based Chatbot for Alcohol Reduction Counseling in MetALD Patients: A Pilot Randomized Controlled Trial
Overview
The goal of this pilot randomized controlled trial is to evaluate the trial feasibility and acceptability of LLM-based chatbot for reducing alcohol use among patients with metabolic alcohol-related liver disease. Specific objectives include: 1. To assess how many MetALD patients accept the invitation to participate in the trial 2. To assess the retention rate of the participants through 3 and 6 months after treatment initiation 3. To assess the acceptability of the LLM-based chatbot in terms of participants' compliance and usability rating 4. To estimate the intervention effect on alcohol reduction 5. To explore the participants' perception and experiences in the chatbot
Interventions
- Behavioral LLM-based chatbot
Over the three months following randomisation, an LLM-based chatbot will interact with each participant individually to deliver four personalized sessions of alcohol reduction information and advice, and participants will also be allowed to contact the chatbot at any time. - Behavioral Telephone counseling
Over the three months following randomisation, a trained counsellor will conduct four individual daytime telephone sessions with each participant to provide personalised information and advice on reducing alcohol consumption. - Behavioral Alcohol Brief Intervention
Brief counselling (5 to 10 mins) to reduce drinking and a self-help booklet
Primary outcome measures
- Recruitment rate [Time frame: Through recruitment completion, about 12 months]
- Retention rate [Time frame: 6 months after randomisation]
- Weekly alcohol consumption [Time frame: 3 months after randomisation]
Secondary outcome measures (10)
- Eligibility rate [Time frame: Through recruitment completion, about 12 months]
- Weekly alcohol consumption [Time frame: 6 months after randomisation]
- Frequency of binge drinking in the past 30 days [Time frame: 3 months after randomisation]
- Frequency of binge drinking in the past 30 days [Time frame: 6 months after randomisation]
- Frequency of heavy drinking in the past 30 days [Time frame: 3 months after randomisation]
- Frequency of heavy drinking in the past 30 days [Time frame: 6 months after randomisation]
- AUDIT score and level [Time frame: 3 months after randomisation]
- AUDIT score and level [Time frame: 6 months after randomisation]
- Planned drinking in the coming 30 days [Time frame: 3 months after randomisation]
- Planned drinking in the coming 30 days [Time frame: 6 months after randomisation]
Eligibility criteria
Inclusion criteria
1\. Hong Kong residents aged 18 years or above 2. Diagnosed of MASLD:
- Evidence of hepatic steatosis (fat accumulation in the liver) confirmed by imaging techniques such as ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), or liver biopsy
- Presence of metabolic dysfunction, indicated by at least one of the following:
- Overweight or obesity (body mass index \[BMI\] ≥25 kg/m²),
- Type 2 diabetes mellitus, ③Dyslipidemia (elevated triglycerides \[≥150 mg/dL\] or low high-density lipoprotein \[HDL\] cholesterol \[<40 mg/dL for men, <50 mg/dL for women\]), ④Hypertension (blood pressure ≥130/85 mmHg or use of antihypertensive medication).
- Metabolic syndrome as defined by established criteria (e.g., International Diabetes Federation \[IDF\], Adult Treatment Panel III \[ATP III\]) 3. Alcohol consumption: males who drink 210-420 g/week (≈263-525 ml), female who drink 140-350 g/week (≈175-438 ml) 4. Intention to reduce/quit alcohol 5. Able to read and communicate in Chinese 6. Own a smartphone with internet access
Exclusion criteria
- Diagnosed with mental disease or cognitive impairments, or
- Participating in other ongoing clinic trials
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Treatment
Study locations
Hong Kong · 1 center
- Hong Kong Queen Mary Hospital — Hong Kong
Identifiers
NCT: NCT07450144 · MetALD